DDInter134 DDInter228
Atovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care. Importantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease.
Atovaquone {u} (Compound) resembles {v} (Compound) Anisindione
Anisindione {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acarbose
Acarbose {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Atovaquone {u} (Compound) resembles {v} (Compound) Mazindol
Mazindol {u} (Compound) resembles {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Brentuximab vedotin
Atovaquone {u} (Compound) resembles {v} (Compound) Anisindione
Anisindione {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Atovaquone {u} (Compound) resembles {v} (Compound) Phenindione
Phenindione {u} (Compound) resembles {v} (Compound) Phenylbutazone
Phenylbutazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Atovaquone {u} (Compound) binds {v} (Gene) DHODH
DHODH {u} (Gene) is bound by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Brentuximab vedotin
Atovaquone {u} (Compound) resembles {v} (Compound) Anisindione
Anisindione {u} may lead to a major life threatening interaction when taken with {v} Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Atovaquone {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Atovaquone {u} (Compound) binds {v} (Gene) DHODH
DHODH {u} (Gene) is downregulated by {v} (Compound) Lovastatin
Lovastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Atovaquone {u} (Compound) resembles {v} (Compound) Anisindione
Anisindione {u} may lead to a major life threatening interaction when taken with {v} Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Atovaquone {u} (Compound) resembles {v} (Compound) Anisindione
Anisindione {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bicalutamide
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Atovaquone (Compound) resembles Anisindione (Compound) and Anisindione may cause a minor interaction that can limit clinical effects when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Atovaquone (Compound) resembles Mazindol (Compound) and Mazindol (Compound) resembles Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Brentuximab vedotin
Atovaquone (Compound) resembles Anisindione (Compound) and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Atovaquone (Compound) resembles Phenindione (Compound) and Phenindione (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Atovaquone (Compound) binds DHODH (Gene) and DHODH (Gene) is bound by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin
Atovaquone (Compound) resembles Anisindione (Compound) and Anisindione may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Atovaquone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Atovaquone (Compound) binds DHODH (Gene) and DHODH (Gene) is downregulated by Lovastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Atovaquone (Compound) resembles Anisindione (Compound) and Anisindione may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Atovaquone (Compound) resembles Anisindione (Compound) and Anisindione may cause a minor interaction that can limit clinical effects when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin